What is William Blair’s Forecast for CRL Q2 Earnings?

Charles River Laboratories International, Inc. (NYSE:CRL) – Stock analysts at William Blair dropped their Q2 2025 earnings per share estimates for shares of Charles River Laboratories International in a research report issued on Wednesday, February 19th. William Blair analyst M. Smock now forecasts that the medical research company will post earnings per share of $2.40 for the quarter, down from their prior forecast of $2.58. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.41 per share. William Blair also issued estimates for Charles River Laboratories International’s FY2025 earnings at $9.36 EPS, Q1 2026 earnings at $2.43 EPS, Q2 2026 earnings at $2.60 EPS and Q3 2026 earnings at $2.63 EPS.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same quarter last year, the firm posted $2.46 earnings per share. Charles River Laboratories International’s revenue was down 1.1% compared to the same quarter last year.

A number of other brokerages also recently commented on CRL. Evercore ISI boosted their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. UBS Group reiterated a “neutral” rating and set a $185.00 price target (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. TD Cowen raised their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a report on Monday, November 11th. Bank of America decreased their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a report on Monday, November 18th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $195.71.

Charles River Laboratories International Trading Down 1.4 %

Shares of CRL stock opened at $162.63 on Friday. Charles River Laboratories International has a fifty-two week low of $150.79 and a fifty-two week high of $275.00. The company has a 50 day moving average price of $173.39 and a 200 day moving average price of $188.81. The stock has a market capitalization of $8.32 billion, a P/E ratio of 1,084.19, a price-to-earnings-growth ratio of 6.77 and a beta of 1.37. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Institutional Investors Weigh In On Charles River Laboratories International

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in Charles River Laboratories International by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock worth $1,136,938,000 after buying an additional 60,497 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Charles River Laboratories International by 9.0% in the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock worth $752,508,000 after purchasing an additional 335,658 shares in the last quarter. State Street Corp grew its stake in shares of Charles River Laboratories International by 2.0% in the third quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after purchasing an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock valued at $330,231,000 after purchasing an additional 47,221 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of Charles River Laboratories International by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock valued at $227,042,000 after purchasing an additional 14,787 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).